Study guide
20.3 Tuberculosis: Pathogenesis & Clinical Manifestations
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
20.3 Tuberculosis: Pathogenesis & Clinical Manifestations
Key Takeaways Explain This Topic AI
Reactivation risk is greatest with HIV infection, TNF inhibitor therapy, chronic kidney disease, diabetes, silicosis and malnutrition.
Pott disease is spinal tuberculosis, typically thoracolumbar with anterior vertebral body destruction and preserved discs early on.
Tuberculous pleural effusion and ascites are lymphocyte-rich exudates with a raised adenosine deaminase.
Last updated: September 2026
Tuberculosis (TB), caused by the acid-fast intracellular pathogen Mycobacterium tuberculosis , remains one of the most critical global infectious diseases. For MRCP(UK) Part 1, candidates must master the immunological pathogenesis of primary versus reactivation infection, distinguish between the protean manifestations of pulmonary and extrapulmonary disease, correctly interpret diagnostic modalities (including the clinical superiority of IGRAs over tuberculin skin testing in BCG-vaccinated cohorts), and demonstrate thorough knowledge of the mechanisms, toxicities, and drug interactions of first-line anti-tuberculous pharmacotherapy.
1. Pathogenesis of Mycobacterium tuberculosis
M. tuberculosis is an obligate aerobe with an exceptionally lipid-rich, waxy cell wall composed of peptidoglycan, arabinogalactan, and mycolic acids , conferring resistance to complement lysis, desiccation, and standard Gram staining.
Inhalation, Phagocytosis & The Primary Complex
Transmission: Spread exclusively via aerosolized droplet nuclei ( 1 – 5 μ m 1\text{–}5\ \mu\text{m} 1 – 5 μ m ) expelled by individuals with active, infectious pulmonary or laryngeal tuberculosis during coughing, sneezing, or speaking.
Alveolar Inoculation: Droplets bypass upper airway mucociliary clearance and deposit in the well-ventilated mid-to-lower subpleural alveoli. Non-activated alveolar macrophages engulf bacilli via mannose receptors and complement receptors.
Inhibition of Phagolysosomal Fusion: Pathogenic M. tuberculosis prevents phagosome maturation into an acidic phagolysosome by secreting cell-wall glycolipids ( cord factor / trehalose 6,6'-dimycolate ) and protein tyrosine phosphatase PtpA. Unrestrained intracellular mycobacterial replication occurs within macrophages, leading to cellular lysis.
The Ghon Complex: Mycobacteria drain via lymphatic channels to regional bronchopulmonary and hilar lymph nodes. The combination of the initial peripheral parenchymal lesion ( Ghon focus ) and the draining calcified regional hilar lymph node is termed the Ghon complex (or Ranke complex once fully fibrocalcified).
Cell-Mediated Immunity & Granuloma Architecture
Between 2 and 6 weeks post-inoculation, dendritic cells present mycobacterial antigens to naive CD4+ T-lymphocytes, priming a robust Type 1 helper T-cell (Th1) adaptive immune response :
Cytokine Orchestration: Th1 cells secrete interferon-gamma (IFN- γ \gamma γ ) , which powerfully activates macrophages, stimulating nitric oxide synthase (iNOS) and reactive oxygen species generation to destroy intracellular mycobacteria. Macrophages and T-cells simultaneously secrete tumour necrosis factor-alpha (TNF- α \alpha α ) , which is essential for recruiting monocytes, organizing granuloma structure, and maintaining vascular integrity around the lesion. Therapeutic inhibition of TNF- α \alpha α (e.g., with infliximab, adalimumab, or etanercept) causes catastrophic breakdown of granuloma architecture and rapid, disseminated reactivation of latent TB.
Caseous Granuloma Formation: The hallmark histopathological lesion consists of central caseous necrosis (hypoxic, acidic, cheese-like acellular debris) surrounded by transformed epithelioid histiocytes , multinucleated Langhans giant cells (horseshoe arrangement of nuclei), and an outer rim of CD4+ and CD8+ T-lymphocytes and fibroblasts.
Latent TB Infection (LTBI) vs. Post-Primary Reactivation
Latent TB Infection (LTBI): In approximately 90 % 90\% 90% of immunocompetent individuals, the immune response successfully seals off viable mycobacteria within calcified granulomas. The host remains asymptomatic, non-infectious, and displays a normal chest radiograph, but demonstrates persistent immunological memory via a positive tuberculin skin test or IGRA.
Post-Primary / Reactivation TB: In 5 – 10 % 5\text{–}10\% 5 – 10% of infected individuals, lifetime reactivation occurs due to waning cell-mediated immunity (aging, malnutrition, HIV infection, end-stage renal disease, anti-TNF therapy, systemic corticosteroids). Reactivation characteristically localizes to the apical and posterior segments of the upper lobes (and superior segments of the lower lobes). These anatomic regions feature the highest ventilation-perfusion ( V / Q V/Q V / Q ) ratios in the lung, producing the highest local alveolar partial pressures of oxygen ( PaO 2 \text{PaO}_2 PaO 2 ), which uniquely favours the replication of this strict aerobe. Extensive tissue liquefaction, cavity formation, and bronchial erosion lead to infectious aerosol production.
- 2. Clinical Manifestations: Pulmonary & Extrapulmonary Tuberculosis
- Pulmonary Tuberculosis
Cardinal Symptoms: Insidious onset of chronic productive cough lasting > 3 weeks > 3\text{ weeks} > 3 weeks , intermittent haemoptysis, low-grade swinging pyrexia (frequently with late-afternoon spikes), drenching nocturnal diaphoresis, progressive anorexia, and unexplained cachexia/weight loss.
Radiological Findings: Upper lobe fibro-cavitary consolidation, volume loss, apical pleural thickening, and traction bronchiectasis. In immunocompromised patients or primary progressive disease, cavitation may be absent, presenting instead with lower lobe consolidation or pleural effusions.
Miliary Tuberculosis: Arises from massive haematogenous dissemination when a caseating focus erodes directly into a pulmonary vein or lymphatic duct. Produces diffuse, non-reactive multiorgan involvement. High-resolution chest radiography or CT demonstrates a pathognomonic diffuse 1–2 mm micronodular 'millet-seed' pattern distributed uniformly throughout both lung fields. Associated with hepatosplenomegaly, bone marrow suppression (pancytopenia), and choroidal tubercles on fundoscopy.
Extrapulmonary Tuberculosis (EPTB)
Extrapulmonary tuberculosis accounts for 15 – 20 % 15\text{–}20\% 15 – 20% of cases in immunocompetent patients and > 50 % > 50\% > 50% of cases in HIV-coinfected individuals.
Tuberculous Lymphadenitis (Scrofula): The most frequent form of extrapulmonary TB. Typically involves the anterior cervical or supraclavicular lymph node chains. Presents as firm, discrete, painless lymphadenopathy that gradually becomes fluctuant, matting together to form a subcutaneous cold abscess (lacking erythema and calor) that may break through the skin to create a chronically draining sinus tract.
Tuberculous Meningitis: The most lethal manifestation. Arises from rupture of a subependymal or subpial caseating tubercle (Rich focus) into the subarachnoid space. Pathologically characterized by a thick, gelatinous basal meningeal exudate encasing the circle of Willis and cranial nerves.
Clinical Presentation: Subacute prodrome (2–3 weeks of headache, malaise, low-grade fever) evolving into signs of raised intracranial pressure, confusion, and isolated cranial nerve palsies ( cranial nerve VI [abducens] is most commonly affected due to its long intracranial course, followed by cranial nerve III).
Complications: Tuberculous vasculitis causing middle cerebral artery territory ischemic stroke (tubercular arteritis), communicating hydrocephalus, and coma.
Tuberculous Spondylitis (Pott's Disease): Infection begins in the anterior subchondral bone of the vertebral body and spreads via the anterior longitudinal ligament across the intervertebral disc into adjacent vertebrae (unlike metastatic spinal malignancy, which characteristically destroys the posterior pedicles and spares the intervertebral disc). Most commonly involves the lower thoracic and upper lumbar spine. Progressive anterior vertebral body collapse causes acute kyphotic angulation (gibbus deformity) . Mycobacterial pus dissects along the psoas muscle sheath to present as a painless, fluctuant psoas cold abscess in the groin or femoral triangle.
Pleural Tuberculosis: Presents as an acute or subacute unilateral exudative pleural effusion. Pleural fluid biochemistry confirms an exudate (protein > 30 g/L > 30\text{ g/L} > 30 g/L ), marked lymphocytic predominance ( > 80 % > 80\% > 80% ) , low glucose, and significantly elevated Adenosine Deaminase (ADA > 40 U/L > 40\text{ U/L} > 40 U/L ) . Direct microscopy is rarely positive ( < 20 % < 20\% < 20% ); closed pleural biopsy (Abrams needle) or thoracoscopic pleural biopsy demonstrates non-caseating/caseating granulomas in > 85 % > 85\% > 85% .
Gastrointestinal Tuberculosis: Acquired via swallowing infected sputum or ingestion of unpasteurized milk ( Mycobacterium bovis ). Predominantly strikes the ileocaecal region due to the abundance of lymphoid tissue (Peyer's patches). Presents with right iliac fossa pain, palpable abdominal mass, fever, bowel obstruction, and mucosal ulcerations, closely mimicking Crohn's disease on endoscopy and CT imaging.
Renal & Urogenital Tuberculosis: Characterized by insidious, destructive papillary necrosis, ureteric strictures, and bladder contracture. The classic laboratory hallmark is sterile pyuria (persistent white blood cells in urine with negative routine bacterial cultures on blood and MacConkey agar; requires 3 early morning urine samples for mycobacterial culture).